Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Data on adenocarcinoma detailed by researchers at Massachusetts General Hospital
June 17th, 2008
According to recent research from the United States, " Pancreatic ductal adenocarcinoma 9PDAC) carries an extremely poor prognosis, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. The development of molecular markers and imaging probes for incipient PDAC would enable earlier detection and guide the development of interventive therapies." "Here we sought to identify novel molecular markers and to test their potential as targeted imaging agents. Methods and Findings Here, a phage display approach was used in a mouse model of PDAC to screen for peptides that specifically bind to cell surface antigens...
Source: Cancer Weekly (2008-06-17)
|
